Nexplanon 68 MG implants
Ended Awarded
- Contract number
- SPE2DB26FUJLW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,886
Award facts
- Contract value 100% obligated
- $13,886.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,886.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nexplanon 68 mg implants. This firm fixed-price delivery order, issued on October 20, 2025, with an ultimate completion date of November 10, 2025, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative—a $30.3 billion acquisition strategy that authorizes DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products and medical consumables to support Department of Defense healthcare operations.
DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier within the federal military medical supply chain, with substantial contracting activity throughout October 2025 spanning oncology treatments, biologics, vaccines, specialty surgical products, and routine pharmaceuticals. The company's performance on numerous delivery orders demonstrates its operational capability to fulfill the diverse and specialized pharmaceutical requirements of the military healthcare system. As a single-award prime vendor contractor under PPV-G GEN V, which carries a ceiling value of $499,999,999 and an ultimate completion date of December 31, 2036, DMS Pharmaceutical Group operates under a 30-month base period with three 30-month option periods, positioning it to serve military healthcare facilities worldwide without identified subcontractor relationships.
Quick answers
Who was awarded contract SPE2DB26FUJLW?
SPE2DB26FUJLW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 20, 2025.
How much is contract SPE2DB26FUJLW worth?
The government has obligated $13,886 on SPE2DB26FUJLW.
Is contract SPE2DB26FUJLW an order under another contract?
Yes. SPE2DB26FUJLW is a delivery order under SPE2DB25D9365, an indefinite delivery contract.
Was contract SPE2DB26FUJLW competed?
The extent of competition for SPE2DB26FUJLW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award